Zydus Lifesciences settles Mirabegron patent dispute with Astellas for $120 mn

• Zydus Lifesciences and its US unit will pay $120 million to Astellas Pharma to resolve a patent dispute over the bladder disorder drug Mirabegron.
• The agreement includes a pre-paid per unit licensing fee on sales of generic Mirabegron in the US until September 2027.
• This settlement allows Zydus to continue marketing its generic Mirabegron in the US.
• The news follows a similar $90 million settlement by competitor Lupin Ltd. with Astellas for the same drug.
• Analysts suggest these settlements could limit generic competition in the US market for a period.